Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Tolerability of Tilrekimig + rHuPH20 in Healthy Participants
NCT07792941Phase 1Active, not recruiting
- Sponsor
- Pfizer
- Start
- Aug 2026
- Primary completion
- Feb 2027
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tilrekimig, sponsored by Pfizer. Primary endpoints: Area under the serum concentration-time curve from time zero to infinity at 150 days and Maximum Observed Plasma Concentration at 150 days. Started Aug 2026; status: active, not recruiting.
02
Drugs
tilrekimig
Beyond the preview
Go deeper on NCT07792941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07792941.